Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Braun J; van den Berg R; Baraliakos X; Boehm H; Burgos-Vargas R; Collantes-Estevez E; Dagfinrud H; Dijkmans B; Dougados M; Emery P; Geher P; Hammoudeh M; Inman RD; Jongkees M; Khan MA; Kiltz U; Kvien T; Leirisalo-Repo M; Maksymowych WP; Olivieri I; Pavelka K; Sieper J; Stanislawska-Biernat E; Wendling D; Ozgocmen S; van Drogen C; van Royen B; van der Heijde DAnn Rheum Dis 2011[Jun]; 70 (6): 896-904This first update of the ASAS/EULAR recommendations on the management of ankylosing spondylitis (AS) is based on the original paper, a systematic review of existing recommendations and the literature since 2005 and the discussion and agreement among 21 international experts, 2 patients and 2 physiotherapists in a meeting in February 2010. Each original bullet point was discussed in detail and reworded if necessary. Decisions on new recommendations were made - if necessary after voting. The strength of the recommendations (SOR) was scored on an 11-point numerical rating scale after the meeting by email. These recommendations apply to patients of all ages that fulfill the modified NY criteria for AS, independent of extra-articular manifestations, and they take into account all drug and non-drug interventions related to AS. Four overarching principles were introduced, implying that one bullet has been moved to this section. There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good.|*Practice Guidelines as Topic[MESH]|Anti-Inflammatory Agents, Non-Steroidal/therapeutic use[MESH]|Antirheumatic Agents/therapeutic use[MESH]|Humans[MESH]|International Cooperation[MESH]|Spondylitis, Ankylosing/drug therapy/*therapy[MESH]|Tumor Necrosis Factor-alpha/antagonists & inhibitors[MESH] |
